Alex Moreland | Cofounder & CEO
Xiretsa
Alex Moreland is co-founder and CEO of Xiretsa, a spinout from UC Santa Barbara which is developing selective membrane-remodeling antibiotics for critical AMR threats. Alex received his B.S. (UCSB, biology & chemistry) in 2012 and his Ph.D. (UCSB, chemistry) in 2019 under the guidance of Professor Guillermo Bazan, designing and synthesizing membrane-intercalating molecules for diverse biotech applications. As a postdoctoral fellow (Cystic Fibrosis Foundation), he demonstrated the utility of the Bazan Lab’s antimicrobial platform against priority gram-negatives and pathogens of concern for people with cystic fibrosis including P. aeruginosa, Burkholderia cepacia complex, and Non-Tuberculous Mycobacteria. Alex is now leading Xiretsa on their mission to combat AMR by developing highly differentiated antibiotics for the greatest unmet needs.
Appearances:
Day 1 - World Antimicrobial Resistance Congress & Disease Prevention Control Summit 2024 @ 12:00
Panel: Navigating the landscape - Strategies for early-stage developmental funding
The panel will address current strategies for early-stage funding chosen by the different panelists and give examples of successful company founding and funding. It will also address gaps and issues with the current funding landscape and within and between the supporting partners, and finally on novel business strategies chosen by the panelists to cope with those gaps. The addressed audience are start-ups, scientists and business developers in the AMR field and those planning to build a start-up, organizations supporting start-ups and everyone interested in early-stage development in the field of AMR.
Sponsored by LifeArc
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events